Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C22H19N5O |
|||
Molecular Weight | 369.42 | CAS No. | 700874-72-2 | |
Solubility (25°C)* | In vitro | DMSO | 73 mg/mL (197.6 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | Galunisertib (LY2157299) is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM in a cell-free assay. Phase 2/3. | ||
---|---|---|---|
Targets |
|
||
In vitro | LY2157299 potently inhibits the TGFβ receptor signaling. LY2157299 abolishes the TGFβ induced Smad2 phosphorylation in HUVEC cells. LY2157299 also shows dose dependent potentiation of VEGF or bFGF induced cell proliferation in HUVEC. LY2157299 also promotes VEGF induced HUVEC cell migration. LY2157299 potentiates angiogenesis in the in vitro VEGF-stimulated cord formation assay. [2] LY2157299 inhibits TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells in a dose-dependent manner. LY2157199 treatment stimulates hematopoiesis from primary MDS bone marrow specimens. [3] In human glioblastoma (GBM) cells, LY2157299 treatment blocks signaling through the heteromeric TGFβ receptor complex to reduce levels of active, phosphorylated SMAD. [4] |
||
In vivo | Although anti-tumor activity has been observed in several pre-clinical models, LY2157299 fails to show significant in vivo angiogenic effects in the 4T1, Colo205, or A549 xenograft models. [2] Administration of LY2157299 ameliorates anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure. [3] Oral administration of LY2157299 at 75 mg/kg/day displays significant antitumor activity against both Calu6 and MX1 xenografts in mice. [5] In vivo, LY2157299 induces angiogenesis and enhances VEGF and basic-fibroblast-growth-factor-induced angiogenesis in a Matrigel-plug assay, whereas adding an alpha5-integrin-neutralizing antibody to the Matrigel selectively inhibits this enhanced response. [6] |
Kinase Assay: |
|
---|---|
Cell Assay: |
|
Animal Study: |
|
Data from [Lab Chip, 2013, 13(10), 1969-78]
Data from [Data independently produced by , , Cancer Research, 2014, 74(21): 5963-77 ]
Data from [Data independently produced by , , Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1346]
Data from [Data independently produced by , , Sci Rep, 2016, 6:23056.]
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence [ Cancer Cell, 2024, 42(9):1507-1527.e11] | PubMed: 39255775 |
Cellular origin and clonal evolution of human dedifferentiated liposarcoma [ Nat Commun, 2024, 15(1):7941] | PubMed: 39266532 |
TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer [ EBioMedicine, 2024, 104:105176] | PubMed: 38810560 |
Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response [ Cell Rep, 2024, 43(8):114532] | PubMed: 39046874 |
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses [ Br J Cancer, 2024, 10.1038/s41416-024-02677-9] | PubMed: 38622286 |
Galunisertib downregulates mutant type I collagen expression and promotes MSCs osteogenesis in pediatric osteogenesis imperfecta [ Biomed Pharmacother, 2024, 175:116725] | PubMed: 38744219 |
CDCA5 promoted cell invasion and migration by activating TGF-β1 pathway in human ovarian cancer cells [ J Ovarian Res, 2024, 17(1):68] | PubMed: 38539247 |
Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy [ Nat Commun, 2023, 14(1):3593] | PubMed: 37328484 |
Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy [ Nat Commun, 2023, 14(1):3593] | PubMed: 37328484 |
Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia [ Cell Rep, 2023, 42(7):112804] | PubMed: 37453060 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.